Journal ArticleDOI
The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients.
Terri S. Armstrong,Terri S. Armstrong,Elizabeth Vera-Bolanos,Ibrahima Gning,Alvina Acquaye,Mark R. Gilbert,Charles S. Cleeland,Tito R. Mendoza +7 more
TLDR
Tumor grade, age, extent of resection, and performance status are established prognostic factors for survival in primary brain tumor patients and development of disease‐related symptoms is predictive of tumor recurrence in other cancers but not in the PBT population.Abstract:
BACKGROUND:
Tumor grade, age, extent of resection, and performance status are established prognostic factors for survival in primary brain tumor (PBT) patients. Development of disease-related symptoms is predictive of tumor recurrence in other cancers but has not been reported in the PBT population.
METHODS:
A cross-sectional sample of 294 PBT patients participated. Progression was based on the radiologist report of the magnetic resonance imaging (MRI). The relation of clinical variables (age, extent of resection, tumor grade, and Karnofsky performance status [KPS]) and MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) mean symptom and interference subscales with progression was examined using logistic regression.
RESULTS:
The study enrolled more men (60%, n = 175); median age was 46 years. The majority had less than a gross total resection (n = 186, 64%), and a good KPS (KPS ≥ 90) (N = 208). The majority had a grade 3 or 4 tumor (n = 199) and 24% of patients had recurrence. Tumor grade and activity-related interference were significantly related to progression. Patients with tumor grade 4 were 2.4 times more likely to have recurrence (95% CI, 1.2-5.; P < .015). Patients with significant (ratings of ≥5) activity-related interference were 3.8 times more likely to have recurrence (95% CI, 2.14-6.80; P < .001). Mean activity-related score was 4.8 for those with progression on MRI and 2.2 for those with stable disease.
CONCLUSIONS:
Significant activity-related interference and tumor grade were associated with recurrence but not KPS, age, or extent of resection. These results provide preliminary support for the use of symptom interference in assessment of disease status. Because the authors used a cross-sectional sample, future studies evaluating change over time are needed. Cancer 2011. © 2011 American Cancer Society.read more
Citations
More filters
Book ChapterDOI
What is Cancer
TL;DR: This chapter discusses different aspects of cancer, a group of many different disorders affecting the different parts of the body, and cancer of one part is quite different from cancer of another part.
Journal ArticleDOI
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
Lakshmi Nayak,Lisa M. DeAngelis,Alba A. Brandes,David M. Peereboom,Evanthia Galanis,Nan Lin,Riccardo Soffietti,David R. Macdonald,Marc C. Chamberlain,James Perry,Kurt A. Jaeckle,Minesh P. Mehta,Roger Stupp,Alona Muzikansky,Elena Pentsova,Timothy F. Cloughesy,Fabio M. Iwamoto,Joerg C. Tonn,Michael A. Vogelbaum,Patrick Y. Wen,Martin J. van den Bent,David A. Reardon +21 more
TL;DR: The NANO scale is designed to combine with radiographic assessment to provide an overall assessment of outcome for neuro-oncology patients in clinical trials and in daily practice and complements existing patient-reported outcomes and cognition testing to combine for a global clinical outcome assessment of well-being among brain tumor patients.
Journal ArticleDOI
The symptom burden of primary brain tumors: evidence for a core set of tumor and treatment-related symptoms
Terri S. Armstrong,Elizabeth Vera-Bolanos,Alvina Acquaye,Mark R. Gilbert,Harshad Ladha,Tito R. Mendoza +5 more
TL;DR: A core set of symptoms, common in other solid tumor patients, that may impact clinical care and assessment of treatment benefit are evaluated in primary brain tumor patients.
Journal ArticleDOI
Sleep-wake disturbance in patients with brain tumors
Terri Armstrong,Marcia Y. Shade,Ghislain Breton,Mark R. Gilbert,Anita Mahajan,Michael E. Scheurer,Elizabeth Vera,Ann M. Berger +7 more
TL;DR: There is increasing evidence for a genetic basis of normal sleep and sleep regulation in healthy adults, and guidelines for assessment and interventions have been developed, with cognitive behavioral therapy, exercise, and sleep hygiene demonstrating benefit in patients with other solid tumors.
Journal ArticleDOI
Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.
Terri S. Armstrong,Allison M. Bishof,Paul D. Brown,Martin Klein,Martin J.B. Taphoorn,Christina Theodore-Oklota +5 more
TL;DR: Identifying a core set of signs/symptoms and functional limitations is important for understanding their clinical impact and is the first step to including clinical outcomes assessment in primary brain tumor clinical trials.
References
More filters
Journal ArticleDOI
The 2007 WHO Classification of Tumours of the Central Nervous System
David N. Louis,Hiroko Ohgaki,Otmar D. Wiestler,Webster K. Cavenee,Peter C. Burger,Anne Jouvet,Bernd W. Scheithauer,Paul Kleihues +7 more
TL;DR: The fourth edition of the World Health Organization (WHO) classification of tumours of the central nervous system, published in 2007, lists several new entities, including angiocentric glioma, papillary glioneuronal tumour, rosette-forming glioneurs tumour of the fourth ventricle, Papillary tumourof the pineal region, pituicytoma and spindle cell oncocytoma of the adenohypophysis.
Book
WHO classification of tumours of the central nervous system
TL;DR: The current edition of the WHO Classification of Tumours of the Central Nervous System will serve as an indispensable textbook for all of those involved in the diagnosis and management of patients with tumors of the CNS, and will make a valuable addition to libraries in pathology, radiology, oncology, and neurosurgery departments.
Journal ArticleDOI
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen,David R. Macdonald,David A. Reardon,Timothy F. Cloughesy,A. Gregory Sorensen,Evanthia Galanis,John DeGroot,Wolfgang Wick,Mark R. Gilbert,Andrew B. Lassman,Christina Tsien,Tom Mikkelsen,Eric T. Wong,Marc C. Chamberlain,Roger Stupp,Kathleen R. Lamborn,Michael A. Vogelbaum,Martin J. van den Bent,Susan M. Chang +18 more
TL;DR: The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
Journal ArticleDOI
The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.
Tito R. Mendoza,X. Shelley Wang,Charles S. Cleeland,Marilyn Morrissey,Beth A. Johnson,Judy K. Wendt,Stephen L. Huber +6 more
TL;DR: The Brief Fatigue Inventory was developed for the rapid assessment of fatigue severity for use in both clinical screening and clinical trials.
Journal ArticleDOI
When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.
TL;DR: In this paper, the authors explored the relationship between numerical ratings of pain severity and ratings of their interference with such functions as activity, mood, and sleep, and found optimal cutpoints that form 3 distinct levels of cancer pain severity that can be defined on a 0-10 point numerical scale.
Related Papers (5)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert,James J. Dignam,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Deborah T. Blumenthal,Michael A. Vogelbaum,Howard Colman,Arnab Chakravarti,Stephanie L. Pugh,Minhee Won,Robert Jeraj,Paul D. Brown,Kurt A. Jaeckle,David Schiff,Volker W. Stieber,David Brachman,Maria Werner-Wasik,Ivo W. Tremont-Lukats,Erik P. Sulman,Kenneth Aldape,Walter J. Curran,Minesh P. Mehta +22 more
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more